A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ

Open source

DOI: 10.1080/14796694.2026.2645982
Published: 2026 Apr
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2645982,
  title = {A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.},
  author = {Johnson ML and Smit EF and Felip E and Ramalingam SS and Ahn MJ and Tsao A and Johnson BE and Offin M and Hussein M and Dagogo-Jack I and Goldman JW and Clarke JM and Negrao MV and Sanborn RE and Morgensztern D and Usari T and Wilner K and Alejandro L and Rifi N and Zhang X and Riely GJ},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2645982},
  url = {https://doi.org/10.1080/14796694.2026.2645982}
}

RIS

TY  - JOUR
TI  - A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
AU  - Johnson ML
AU  - Smit EF
AU  - Felip E
AU  - Ramalingam SS
AU  - Ahn MJ
AU  - Tsao A
AU  - Johnson BE
AU  - Offin M
AU  - Hussein M
AU  - Dagogo-Jack I
AU  - Goldman JW
AU  - Clarke JM
AU  - Negrao MV
AU  - Sanborn RE
AU  - Morgensztern D
AU  - Usari T
AU  - Wilner K
AU  - Alejandro L
AU  - Rifi N
AU  - Zhang X
AU  - Riely GJ
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2645982
UR  - https://doi.org/10.1080/14796694.2026.2645982
ER  -

APA

ML, J., EF, S., E, F., SS, R., MJ, A., A, T., BE, J., M, O., M, H., I, D., JW, G., JM, C., MV, N., RE, S., D, M., T, U., K, W., L, A., N, R., X, Z., & GJ, R. (2026). A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2645982

Source records

pubmed · retrieved 2026-09-26T01:23:23.673Z